STOCK TITAN

Viridian Therapeutics (VRDN) 10-K Filings

VRDN NASDAQ

Here are the 10-K annual reports from Viridian Therapeutics, Inc. (VRDN) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow VRDN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VRDN filings page.

Rhea-AI Summary

Viridian Therapeutics details its shift toward commercialization in serious and rare autoimmune diseases, led by thyroid eye disease (TED) programs. Lead IV antibody veligrotug has completed two global phase 3 trials in active and chronic TED, with a BLA under FDA Priority Review and a PDUFA target date of June 30, 2026. Subcutaneous follow‑on antibody elegrobart is in two phase 3 REVEAL studies, with topline data expected in the first and second quarters of 2026 and an auto‑injector in development for at‑home use. Viridian is also advancing FcRn inhibitors VRDN‑006 and VRDN‑008, plus an early anti‑TSHR antibody for Graves’ disease and TED. Non‑dilutive funding includes a $70 million Japan collaboration with Kissei and a revenue participation deal with DRI Healthcare for up to $300 million tied to U.S. sales milestones.